Literature DB >> 8253955

Expression of A and B subunits of Shiga-like toxin II as fusions with glutathione S-transferase and their potential for use in seroepidemiology.

F Gunzer1, H Karch.   

Abstract

We used the plasmid vector pGEX-2T for the expression of recombinant subunits of Shiga-like toxin II (SLT-II). The 5' terminus of the genes that code for either the SLT-IIA or SLT-IIB subunits was genetically fused to the 3' terminus of the gene coding for the enzyme glutathione S-transferase, which serves as a carrier in this expression system. The subunit genes were constructed synthetically by polymerase chain reaction, with appropriate restriction sites to permit in-frame downstream insertion of the genes. The resulting plasmids containing the A and B subunit genes were designated pFG1 and pFG2, respectively. Induction of Escherichia coli laboratory strains harboring pFG1 with isopropyl-beta-D-thiogalactopyranoside (IPTG) yielding only small quantities of SLT-IIA fusion proteins. Since IPTG induction was lethal for cells harboring pFG2, we constructed the recombinant plasmid pFG4, which contained a subgenic fragment of slt-IIB but without the 5' signal sequence. With this construct we were able to express very large quantities of a 33.5-kDa fusion protein, which was purified by affinity chromatography on immobilized glutathione and used as an antigen in immunoblot analysis. Rabbit serum against native SLT-II, as well as all of 12 serum samples with high neutralizing activity against SLT-II, reacted with SLT-IIB purified from an E. coli pFG4 expression system, whereas only 3 of 208 human serum samples with low neutralization titers and none of 54 serum samples with no SLT-II-neutralizing capability reacted. Failure of specific reactivity with the SLT-IIB fusion protein in the majority of human serum samples with low neutralizing activity suggests that serum factors other than immunoglobulins may be responsible for neutralizing activity in these cases. The immunoblot assay with recombinant SLT-IIB as the antigen can be recommended for use in a diagnostic setting as a simple and reliable approach to detect specific human serum antibodies to SLT-II.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8253955      PMCID: PMC265944          DOI: 10.1128/jcm.31.10.2604-2610.1993

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  21 in total

1.  Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa.

Authors:  H Schägger; G von Jagow
Journal:  Anal Biochem       Date:  1987-11-01       Impact factor: 3.365

2.  Purified verotoxins of Escherichia coli O157:H7 decrease prostacyclin synthesis by endothelial cells.

Authors:  H Karch; M Bitzan; R Pietsch; K O Stenger; H von Wulffen; J Heesemann; R Düsing
Journal:  Microb Pathog       Date:  1988-09       Impact factor: 3.738

3.  Cloning of genes determining the production of vero cytotoxin by Escherichia coli.

Authors:  G A Willshaw; H R Smith; S M Scotland; B Rowe
Journal:  J Gen Microbiol       Date:  1985-11

4.  Anticytotoxin-neutralizing antibodies in immune globulin preparations: potential use in hemolytic-uremic syndrome.

Authors:  S Ashkenazi; T G Cleary; E Lopez; L K Pickering
Journal:  J Pediatr       Date:  1988-12       Impact factor: 4.406

5.  Isolation and characterization of monoclonal antibodies to Shiga-like toxin II of enterohemorrhagic Escherichia coli and use of the monoclonal antibodies in a colony enzyme-linked immunosorbent assay.

Authors:  L P Perera; L R Marques; A D O'Brien
Journal:  J Clin Microbiol       Date:  1988-10       Impact factor: 5.948

6.  DNA sequence analysis with a modified bacteriophage T7 DNA polymerase.

Authors:  S Tabor; C C Richardson
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

7.  The role of Escherichia coli O 157 infections in the classical (enteropathic) haemolytic uraemic syndrome: results of a Central European, multicentre study.

Authors:  M Bitzan; K Ludwig; M Klemt; H König; J Büren; D E Müller-Wiefel
Journal:  Epidemiol Infect       Date:  1993-04       Impact factor: 2.451

8.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

Review 9.  Infection by verocytotoxin-producing Escherichia coli.

Authors:  M A Karmali
Journal:  Clin Microbiol Rev       Date:  1989-01       Impact factor: 26.132

10.  The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli.

Authors:  M A Karmali; M Petric; C Lim; P C Fleming; G S Arbus; H Lior
Journal:  J Infect Dis       Date:  1985-05       Impact factor: 5.226

View more
  7 in total

1.  Polyclonal antibodies to glutathione S-transferase--verotoxin subunit a fusion proteins neutralize verotoxins.

Authors:  P H M Leung; J S M Peiris; W W S Ng; W C Yam
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

2.  Control of enterohaemorrhagic Escherichia coli infection: the need for a network involving microbiological laboratories and clinical and public health institutions.

Authors:  H Karch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-04       Impact factor: 3.267

3.  A standard immunoglobulin preparation produced from bovine colostra shows antibody reactivity and neutralization activity against Shiga-like toxins and EHEC-hemolysin of Escherichia coli O157:H7.

Authors:  R Lissner; H Schmidit; H Karch
Journal:  Infection       Date:  1996 Sep-Oct       Impact factor: 3.553

4.  Serodiagnosis of Porphyromonas gingivalis infection by immunoblot analysis with recombinant collagenase.

Authors:  M Wittstock; T F Flemmig; H Schmidt; R Mutters; H Karch
Journal:  J Clin Microbiol       Date:  1996-10       Impact factor: 5.948

5.  Antibody response to Shiga toxins Stx2 and Stx1 in children with enteropathic hemolytic-uremic syndrome.

Authors:  K Ludwig; M A Karmali; V Sarkim; C Bobrowski; M Petric; H Karch; D E Müller-Wiefel
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

6.  Expression and purification of Shiga-like toxin II B subunits.

Authors:  D W Acheson; S A De Breucker; M Jacewicz; L L Lincicome; A Donohue-Rolfe; A V Kane; G T Keusch
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

7.  Clonal relatedness of Shiga-like toxin-producing Escherichia coli O101 strains of human and porcine origin.

Authors:  S Franke; D Harmsen; A Caprioli; D Pierard; L H Wieler; H Karch
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.